SEC Tracker
Get the app

Vistagen Therapeutics VTGN

Vistagen Therapeutics (VTGN) has filed its fiscal Q2 2026 Form 10-Q, providing investors with an update on the company's financial performance and operational progress. The filing highlights the company's ongoing clinical development of its novel CNS therapeutics pipeline, which is of keen interest to investors tracking Vistagen's long-term growth potential in the rapidly evolving mental health treatment market.

Form
10-Q
Filed
Importance
Notable

Open in the appGet the appView on EDGAR

Get an email when Vistagen Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Agenus AGEN public float $135M, Jun 30, 2025
  2. Voyager Therapeutics VYGR public float $144M, Jun 30, 2025
  3. Eledon Pharmaceuticals ELDN public float $145M, Jun 30, 2025
  4. Puma Biotechnology PBYI public float $145M, Jun 30, 2025
  5. Neurogene NGNE public float $146M, Jun 30, 2025